National Bank of Canada FI Buys 11,996 Shares of Sanofi (NASDAQ:SNY)

National Bank of Canada FI lifted its stake in Sanofi (NASDAQ:SNY) by 3.5% during the first quarter, HoldingsChannel reports. The firm owned 350,895 shares of the company’s stock after purchasing an additional 11,996 shares during the period. National Bank of Canada FI’s holdings in Sanofi were worth $17,281,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Salem Investment Counselors Inc. bought a new position in Sanofi during the 4th quarter worth about $27,000. Venturi Wealth Management LLC grew its holdings in Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after acquiring an additional 332 shares in the last quarter. Frazier Financial Advisors LLC bought a new position in Sanofi during the 4th quarter worth about $28,000. Register Financial Advisors LLC purchased a new stake in shares of Sanofi during the first quarter valued at about $29,000. Finally, Larson Financial Group LLC lifted its position in shares of Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Up 1.5 %

Shares of SNY stock traded up $0.77 during mid-day trading on Wednesday, hitting $51.20. 2,122,180 shares of the stock traded hands, compared to its average volume of 2,132,923. The stock has a market cap of $129.68 billion, a P/E ratio of 25.73, a P/E/G ratio of 1.59 and a beta of 0.59. The stock’s fifty day moving average is $49.05 and its two-hundred day moving average is $48.68. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, April 25th. The company reported $0.96 EPS for the quarter, meeting the consensus estimate of $0.96. The business had revenue of $11.36 billion during the quarter, compared to analyst estimates of $11.75 billion. Sanofi had a net margin of 10.52% and a return on equity of 26.25%. Equities analysts predict that Sanofi will post 4.14 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.